Neuronetics Statistics
Total Valuation
Neuronetics has a market cap or net worth of $108.16 million. The enterprise value is $111.42 million.
| Market Cap | 108.16M |
| Enterprise Value | 111.42M |
Important Dates
The next confirmed earnings date is Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Neuronetics has 29.76 million shares outstanding. The number of shares has increased by 6.54% in one year.
| Shares Outstanding | 29.76M |
| Shares Change (YoY) | +6.54% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 6.32% |
| Owned by Institutions (%) | 65.25% |
| Float | 21.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.56 |
| Forward PS | 1.38 |
| PB Ratio | 3.26 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 1.83.
| Current Ratio | 4.73 |
| Quick Ratio | 3.96 |
| Debt / Equity | 1.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.57 |
Financial Efficiency
Return on equity (ROE) is -72.80% and return on invested capital (ROIC) is -31.61%.
| Return on Equity (ROE) | -72.80% |
| Return on Assets (ROA) | -29.30% |
| Return on Capital (ROIC) | -31.61% |
| Revenue Per Employee | $351,468 |
| Profits Per Employee | -$148,714 |
| Employee Count | 203 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.31 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.92% in the last 52 weeks. The beta is 2.44, so Neuronetics's price volatility has been higher than the market average.
| Beta (1Y) | 2.44 |
| 52-Week Price Change | +68.92% |
| 50-Day Moving Average | 3.89 |
| 200-Day Moving Average | 2.44 |
| Relative Strength Index (RSI) | 40.38 |
| Average Volume (30 Days) | 170,343 |
Short Selling Information
The latest short interest is 94,569, so 0.32% of the outstanding shares have been sold short.
| Short Interest | 94,569 |
| Short Previous Month | 53,175 |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, Neuronetics had revenue of $71.35 million and -$30.19 million in losses. Loss per share was -$1.05.
| Revenue | 71.35M |
| Gross Profit | 51.71M |
| Operating Income | -30.55M |
| Pretax Income | -30.19M |
| Net Income | -30.19M |
| EBITDA | -22.76M |
| EBIT | -24.77M |
| Loss Per Share | -$1.05 |
Balance Sheet
The company has $62.64 million in cash and $62.47 million in debt, giving a net cash position of $164,000 or $0.01 per share.
| Cash & Cash Equivalents | 62.64M |
| Total Debt | 62.47M |
| Net Cash | 164,000 |
| Net Cash Per Share | $0.01 |
| Equity / Book Value | 34.19M |
| Book Value Per Share | 1.15 |
| Working Capital | 73.98M |
Cash Flow
In the last 12 months, operating cash flow was -$32.04 million and capital expenditures -$2.37 million, giving a free cash flow of -$34.41 million.
| Operating Cash Flow | -32.04M |
| Capital Expenditures | -2.37M |
| Free Cash Flow | -34.41M |
| FCF Per Share | -$1.20 |
Margins
Gross margin is 72.47%, with operating and profit margins of -42.82% and -42.31%.
| Gross Margin | 72.47% |
| Operating Margin | -42.82% |
| Pretax Margin | -42.31% |
| Profit Margin | -42.31% |
| EBITDA Margin | -31.90% |
| EBIT Margin | -34.71% |
| FCF Margin | -48.22% |
Dividends & Yields
Neuronetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.54% |
| Shareholder Yield | -6.54% |
| Earnings Yield | -27.05% |
| FCF Yield | -30.83% |
Analyst Forecast
The average price target for Neuronetics is $10.00, which is 173.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.00 |
| Price Target Difference | 173.97% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 15.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Neuronetics has an Altman Z-Score of -3.05 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.05 |
| Piotroski F-Score | 2 |